Two Sigma Investments LP Reduces Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Two Sigma Investments LP cut its holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 57.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,304 shares of the company’s stock after selling 41,248 shares during the period. Two Sigma Investments LP’s holdings in Corvus Pharmaceuticals were worth $162,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Three Bridge Wealth Advisors LLC bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth $120,000. Nwam LLC boosted its stake in Corvus Pharmaceuticals by 54.2% in the 4th quarter. Nwam LLC now owns 15,500 shares of the company’s stock worth $83,000 after purchasing an additional 5,450 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Corvus Pharmaceuticals by 91.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 29,968 shares of the company’s stock valued at $160,000 after buying an additional 14,300 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Corvus Pharmaceuticals during the 4th quarter valued at about $583,000. Finally, American Century Companies Inc. grew its holdings in Corvus Pharmaceuticals by 140.4% during the 4th quarter. American Century Companies Inc. now owns 43,774 shares of the company’s stock valued at $234,000 after buying an additional 25,566 shares in the last quarter. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CRVS shares. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 20th. Oppenheimer reiterated an “outperform” rating and issued a $17.00 target price (up from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. Mizuho set a $11.00 price target on shares of Corvus Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, May 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Corvus Pharmaceuticals Price Performance

Shares of CRVS opened at $4.24 on Friday. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.75 and a 1-year high of $10.00. The company has a market capitalization of $289.04 million, a P/E ratio of -4.56 and a beta of 0.57. The firm’s 50 day simple moving average is $3.57 and its 200 day simple moving average is $4.68.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). On average, equities analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.